---
source_pdf: "https://drive.google.com/file/d/13wiaQML_BvbXiuR79X64rHsxXycFrm3R/view"
drive_folder: "Portfolio/Prudentia"
type: portfolio
company: Prudentia
ingested: 2025-12-27
original_filename: "Prudentia Sciences Series A.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/13wiaQML_BvbXiuR79X64rHsxXycFrm3R/view)

## Slide 1: Company Overview

**Prudentia Sciences**
Accelerated Insights, Prudent Decisions

**Company Overview**
Prudentia Sciences
2025

September 2025
Confidential - Do Not Distribute
Prudentia Sciences

## Slide 2: Prudentia Sciences is building the future of drug dealmaking with:

**Prudentia Sciences**

Prudentia Sciences is building the future of drug dealmaking with:
*   AI powered clinical evaluation of drugs
*   Valuation tied to clinical progress and risks

September 2025
Confidential - Do Not Distribute
2

## Slide 3: Team Introductions

**Prudentia Sciences**

**Team Introductions**
Prudentia Sciences Team

| Name                 | Role                      | Previous Experience                                             |
| :------------------- | :------------------------ | :-------------------------------------------------------------- |
| Sadiqa Mahmood       | CEO & Founder             | Ex - Health Catalyst, Broad Institute of Harvard & MIT, Mass General Brigham |
| Nate Fox             | Chief Technology Officer  | Ex - H1, Ribbon Health, Microsoft                               |
| Sharon Tan           | Scientific Lead           | Ex - Ultragenyx, enGene, Enzyvent, Genzyme, Boston Scientific   |
| Ben Klein            | Head of Partnerships      | Ex - Flatiron Health, Optum                                     |
| John Reynders, PhD   | Head of Strategy          | Ex - Moderna, Alexion, J&J                                      |

September 2025
Confidential - Do Not Distribute
3

## Slide 4: Scientific Advisory Board and Expert Panel

**Prudentia Sciences**

**Scientific Advisory Board and Expert Panel**

| Name                     | Role / Experience                                                                        |
| :----------------------- | :--------------------------------------------------------------------------------------- |
| Mark Currie, PhD (SAB Chair) | Board Director, Ironwood Pharmaceuticals; Board Director, Science Exchange; Pioneered discovery of drugs like Celebrex, Lunesta, and Linzess |
| Mary Lynne Hedley        | Board Member, Eli Lilly and Veeva; Venture Partner, Third Rock Ventures; Pioneered discovery and approval of Tesaro |
| David Nicholson, PhD     | Executive Vice President and Chief R&D Officer at Allergan; Chief Technology Officer and EVP, R&D at Bayer; Pioneered discovery of anti-PD1 cancer drug Keytruda® (pembrolizumab) |
| Matt Leoni, MD           | CMO, Merida Biosciences; SVP Global Clinical Development, Cerevel Therapeutics; Senior Director, CNS, Global Clinical Development, Otsuka; Lead Medical Director, Neuroscience, US Early Development, Novartis |
| Ana Cristina Puga, MD, PhD | Head of Early Development, Sarepta Therapeutics; VP, Clinical Development CNS, Bluerock Therapeutics; Medical Director, Rare Diseases, Sanofi |
| Stuart Chaffee           | CEO, QuantX Biosciences; Co-Founder and Head of BD, Kymera Therapeutics (IPO); CBO of Affinivax (acquired by GSK); CBO & CFO, Praxis Precision Medicines (IPO) |

**Company Logos:**
Lilly, Cerevel, Novartis, Otsuka, Praxis, Kymera, Merck, Veeva, AbbVie

October 2025
Confidential - Do Not Distribute
4

## Slide 5: The Challenge in Drug Transactions across Life Sciences Sector

**Prudentia Sciences**

**The Challenge in Drug Transactions across Life Sciences Sector**
Unlocking Value in $1.5T Drug Dealmaking Market

These questions reflect the realities of the current market landscape. At the outset, there are several challenges including:

*   “What is the highest value decision I can make for my pipeline?”
*   "How can I beat the competition for the next great asset?"
*   “How do I optimize valuation of my asset?"

? Immense Capital at Risk
? Systemic Inefficiencies
? Data Overload, Insight Scarcity
? Gap in Valuation and Clinical Risks
? Lack of Enterprise Tools

September 2025
Confidential - Do Not Distribute
5

## Slide 6: Ideal State

**Prudentia Sciences**

**Ideal State**
AI Native Approach for Data Driven Deal Making

*   Accelerate speed to decision – from data room access to submission of a competitive bid.
*   Scale diligence team and deal throughput per year.
*   Ensure no stone left unturned, and quickly identify value driver or risk.
*   Achieve optimal bid based on clinical milestones and risks.

September 2025
Confidential - Do Not Distribute
6

## Slide 7: Prudentia is building scientific due diligence platform for global drug asset transactions

**Prudentia Sciences**

**Prudentia is building scientific due diligence platform for global drug asset transactions**
In just 2 years, we have

**>70**
Drug Assessments
6 Therapeutic Areas

**~$5m**
End of 2025 Sales
Pharma ACV >$1m
Biotech & VC ACV >$125k

**>8**
End of 2025
Enterprise Customers

**$17.21m**
Pipeline deal amount

**Deals in active discussions**

| Category         | Count |
| :--------------- | :---- |
| Biopharma        | 14    |
| Biotech          | 7     |
| Investor/VC      | 13    |
| LS consulting    |       |

Highly active pipeline with significant pharma, biotech & investor interest

7

## Slide 8: Prudentia is Unleashing a $264m Annual Revenue Opportunity

**Prudentia Sciences**

**Prudentia is Unleashing a $264m Annual Revenue Opportunity**
Capturing 5% of a $5.3B TAM

**$10.5B TAM**

**Prudentia Platform**
Drug diligence and staging

| Target Addressable Market (TAM) | Description                 | Average Deal Size (ARR)         |
| :------------------------------ | :-------------------------- | :------------------------------ |
| $8.25b                          | 5500 Global Pharma          | ~$1.5m                          |
| $1.87b                          | 15,000 Biotech              | ~$125k                          |
| $437m                           | 455 Financial Institutions\* | ~$95k (VCs) - $2m (IB)          |

\*103 VCs + 149 PEs + 203 Investment Banks

August 2025
Confidential - Do Not Distribute

8

## Slide 9: Our Solution - End-to-End Drug Assessment & Valuation Platform

**Prudentia Sciences**

**Our Solution**
End-to-End Drug Assessment & Valuation Platform

**Prudentia Sciences Platform Features**
*   Traceable AI
*   SOC 2 Enabled

**Platform Components:**
*   **Prism:** Drug Assessment
*   **Pinnacle:** Value Simulation
*   **Pulse:** Staging of Drugs
*   **Prospect:** Top-of-funnel synthesis
*   Expert in the loop

August 2025
Confidential - Do Not Distribute

## Slide 10: Prudentia Solutions Mapped to Drug Due Diligence Process

**Prudentia Sciences**

**Prudentia Solutions Mapped to Drug Due Diligence Process**
End-to-End Deal Management, Diligence & Valuation Platform

| Stages    | Activity                                                                                                                                                                                                                                      | Prudentia Solutions    |
| :-------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | :--------------------- |
| Stage I   | **Opportunity Screening and Prioritization**<br>● Dynamic Deal Funnel Management & Opportunity Sizing<br>● On-Strategy Alignment w/ Portfolio Priority                                                                                   | Prospect               |
| Stage II  | **Asset Assessment and Valuation**<br>● Domain-Specific Diligence w/ Expert Alignment<br>● Deep Market Review & Optimal Valuation Scenarios<br>● Competitive Landscape Assessment                                                            | Prism, Pinnacle & Pattern |
| Stage III | **Deal Execution and Integration**<br>● Decision Analysis and Governance<br>● Deal Execution and Post-Diligence Integration                                                                                                                |                        |

**Deal Flow Diagram:**
>1000 Deals (e.g., sources from JPM, BIO, etc.)
↓
Prudentia Sciences
↓
<20 high quality deals
↓
Deal Executed

September 2025
Confidential - Do Not Distribute
10

## Slide 11: Success Metrics

**Prudentia Sciences**

**Success Metrics**
How Our Partners Measure Success

| Metric                   | Value   | Description                                        |
| :----------------------- | :------ | :------------------------------------------------- |
| Accelerated Diligence Cycle | 12 Weeks ↓ 1 Day | For scientific review                              |
| Quick Screening           | 2 Weeks ↓ Instant | Of High Value Opportunities                        |
| Reduce Diligence Burden and Risk for Transaction Teams | 5 Weeks ↓ 1 Hour | For scientific review                              |
| Rapid Simulation          | 4 Weeks ↓ Instant | Of 100s of Scenarios with Clinical Progress and Risks |

August 2025
Confidential - Do Not Distribute
11

## Slide 12: The Prudentia Advantage

**Prudentia Sciences**

**The Prudentia Advantage**

**Accelerate Deal Timelines with Quick Decision Making**
*   Rapidly disqualify bad deals
*   Focus on high-potential, transformative opportunities
*   Reduce diligence costs and deploy resources to high-value opportunities

**Dual-Sided Platform Driving Network Effects**
*   Uniquely serves both buy-side and sell-side transactions across biotechs, pharma, and investors
*   Creates a powerful network effect and comprehensive market coverage

**From Static Snapshots to Continuous, Contextual Diligence**
*   Move beyond static due diligence to an "always-on" platform capturing evolving asset value – a critical, unmet need.
*   Contextualize clinical, market, regulatory data sets with the asset information.

Confidential - Do Not Distribute

## Slide 13: Case Study - Biotech diligence identified previously unknown risks and drive meaningful NPV impact

**Prudentia Sciences**

**Case Study**
Biotech diligence identified previously unknown risks and drive meaningful NPV impact

**Biotech Drug Assessment with Valuation and Risk Simulation**

**SITUATION**
*   A biotechnology company approached Prudentia Sciences with the need to thoroughly assess their early-stage development asset in the Neurology.
*   The company was pursuing external investment and needed support in staging their asset, identifying potential risks, and driving valuation estimates.

**APPROACH**
*   Company leveraged Prudentia's Prism and Pinnacle solutions to comprehensively assess their asset across multiple indications and understand NPV scenarios based on numerous variables pulled from the diligence.
*   Company integrated their data room directly with Prudentia's solution.

**IMPACT**
*   Prudentia solution identified 2 high-risk safety concerns which were previously unknown by Company. This allowed them to proactively address with supplemental data prior to approaching potential investors, directly impacting their NPV.

**Quote:**
“Prudentia’s platform helped us rapidly identify potential NPV-impacting variables within our safety & toxicology profile, and with such speed that we were able to proactively supplement prior to investor presentations.”
— CEO, Biotech

Confidential - Do Not Distribute

## Slide 14: Case Study - Venture Capital firm identified key value drivers and risks

**Prudentia Sciences**

**Case Study**
Venture Capital firm identified key value drivers and risks

**Biotech Diligence & Valuation / Risk Simulation**

**SITUATION**
*   A venture capital firm had an influx of potential investment opportunities and needed to rapidly perform an in-depth diligence on one key potential biotech investment - time was a limiting factor.

**APPROACH**
*   Company leveraged Prudentia's Prism to assess biotech asset, including clinical, scientific and commercial components.
*   Company integrated their data room directly with Prudentia's solution (>80 data files)

**IMPACT**
*   Prudentia delivered a comprehensive diligence assessment in <15 minutes upon completion of the data room upload.
*   Prism identified a number of potential risks across key domains such as regulatory and CMC, however ultimately showcased a valuable diligence that enabled the VC firm to move forward with the investment quickly.

**Quote:**
"I wish I had this tool 4-5 months ago, as I was working on a diligence process with several colleagues where we evaluated over 100+ immunology & oncology assets...This would be invaluable for the many other newco/venture teams that are also going through this similar process."
— Partner, VC

Confidential - Do Not Distribute

## Slide 15: Case Study - Biopharma addressing major enterprise-wide pain points via AI-powered diligence

**Prudentia Sciences**

**Case Study**
Biopharma addressing major enterprise-wide pain points via AI-powered diligence

**Biotech Diligence & Valuation / Risk Simulation**

**SITUATION**
*   A top 20 global biopharma company engaged with Prudentia to help address key pain points in their pursuit for external innovation - specifically:
    *   Slow diligence process that lacks enterprise technology
    *   Painful stakeholder management process to support diligence completion
    *   Lack of consistent framework for assessing external assets

**APPROACH**
*   Company engaged with Prudentia to address these pain points via Prudentia's enterprise platform (Prospect, Prism, Pinnacle)
*   Prudentia presented holistic enterprise approach:
    *   **Prospect** - help manage influx of top-of-funnel deals to identify potential opportunities for further evaluation
    *   **Prism** - dramatically accelerate scientific, regulatory and commercial diligence from weeks to hours
    *   **Pinnacle** - evaluate potential valuation and risk scenarios based on commercial, regulatory, and scientific findings

**Ongoing**

**Quote:**
“We are constantly chasing internal experts for diligence and continue to run an inefficient process. Prudentia is doing this in minutes and we have full provenance of data.”
— VP, BD&L - Top 200 Biopharma

Confidential - Do Not Distribute

## Slide 16: Competitive Landscape

**Prudentia Sciences**
**Prudentia Sciences**

**Competitive Landscape**

**Y-Axis (from top to bottom):**
*   AI-native Platform
*   Tech-enabled Consulting Services
*   Consulting Services

**X-Axis (from left to right):**
*   Market Intelligence
*   Financial Modeling
*   Scientific Assessment
*   Comprehensive Scientific Assessment + Valuation

**Companies on the Landscape:**

*   **AI-native Platform:**
    *   Prudentia Sciences
    *   Evaluate (a norstella company)
    *   Clarivate™
    *   AlphaSense
*   **Consulting Services / Scientific Assessment / Comprehensive Scientific Assessment + Valuation:**
    *   QLS
    *   BCG
    *   LEK™

Confidential - Do Not Distribute
16

## Slide 17: Raising $25m

**Prudentia Sciences**

**Raising $25m**
Use of Proceeds

**Pie Chart Data:**
*   Scale Core Platform: 35.0%
*   Build Language Models: 30.0%
*   New Solutions: 20.0%
*   Expand to China: 15.0%

August 2025
Confidential - Do Not Distribute
17

## Slide 18: Vision

**Prudentia Sciences**

**Vision**

End to end platform for drug dealmaking

**Process Steps:**

1.  **Staging**
    *   Prepare for evaluation
2.  **Diligence**
    *   Clinical assessment
3.  **Valuation**
    *   Optimal bid
4.  **Deal Execution**
    *   Partnering

August 2025
Confidential - Do Not Distribute
18